There are now UK sites open and recruiting newly diagnosed chronic phase patients for this study which compares 400mg imatinib (Glivec) with 600mg or 800mg nilotinib (Tasigna).
See Newswire August 21 box.
For further details and names of all participating centres open so far see link to clinicaltrials.gov on Newswire August 16th box.
ENESTnd is a phase III randomized, open-label, multicenter study comparing the efficacy and safety of nilotinib versus Glivec®/Gleevec®* (imatinib) in adult patients with newly diagnosed Ph+ CML in the chronic phase.
Patients will be randomized to nilotinib 400 mg BID, nilotinib 300 mg BID, or Glivec/Gleevec 400 mg QD. ENESTnd will be open in 220 global sites.